Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Sep 24, 2024; 15(9): 1232-1238
Published online Sep 24, 2024. doi: 10.5306/wjco.v15.i9.1232
Successful cetuximab rechallenge in metastatic colorectal cancer: A case report
Alexandra Guedes, Sandra Silva, Sandra Custódio, Andreia Capela
Alexandra Guedes, Sandra Silva, Sandra Custódio, Andreia Capela, Department of Medical Oncology, Centro Hospitalar Gaia/Espinho, Vila Nova de Gaia 4434-502, Portugal
Author contributions: Guedes A contributed to manuscript writing and editing, and data collection; Silva S contributed to data analysis; Capela A contributed to conceptualization and supervision; Custódio S was the patient’s attending physician. All authors have read and approved the final manuscript.
Supported by an Independent Medical Writing Grant by Merck KGaA, Darmstadt (internal code ARL-007614).
Informed consent statement: Informed written consent could not be obtained from the patient as he died in 2019.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Alexandra Guedes, MD, Doctor, Department of Medical Oncology, Centro Hospitalar Gaia/Espinho, Rua Conceição Fernandes S/N, Vila Nova de Gaia 4434-502, Portugal. alexandra.pereira.guedes@ulsge.min-saude.pt
Received: March 4, 2024
Revised: July 22, 2024
Accepted: August 15, 2024
Published online: September 24, 2024
Processing time: 177 Days and 21.7 Hours
Core Tip

Core Tip: In RAS-wild type patients treated with anti-epidermal growth factor receptor inhibitors, the emergence of RAS mutations leads to resistance to further anti-epidermal growth factor receptor treatment. However, resistant clones seem to decay over time upon treatment withdrawal. Liquid biopsy-driven cetuximab rechallenge can be effective in later lines of treatment of metastatic colorectal cancer. Longer anti-epidermal growth factor receptor-free intervals may act as a surrogate for improved responses and survival outcomes.